Cartesian Therapeutics Valuation
| RNAC Stock | 6.68 0.08 1.18% |
At this time, the firm appears to be undervalued. Cartesian Therapeutics shows a prevailing Real Value of USD13.68 per share. The current price of the firm is USD6.68. Our model approximates the value of Cartesian Therapeutics from analyzing the firm fundamentals such as Return On Equity of -70.29, operating margin of (46.61) %, and Shares Outstanding of 26 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cartesian Therapeutics' valuation include:
Price Book 31.2575 | Enterprise Value | Enterprise Value Ebitda (1.17) | Price Sales 161.1223 | Forward PE 25.4453 |
Undervalued
Today
Please note that Cartesian Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Cartesian Therapeutics is based on 3 months time horizon. Increasing Cartesian Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cartesian Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cartesian Stock. However, Cartesian Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.68 | Real 13.68 | Target 35.29 | Hype 6.61 | Naive 5.67 |
The real value of Cartesian Stock, also known as its intrinsic value, is the underlying worth of Cartesian Therapeutics Company, which is reflected in its stock price. It is based on Cartesian Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cartesian Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cartesian Therapeutics helps investors to forecast how Cartesian stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cartesian Therapeutics more accurately as focusing exclusively on Cartesian Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cartesian Therapeutics' intrinsic value based on its ongoing forecasts of Cartesian Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cartesian Therapeutics' closest peers. If more than one evaluation category is relevant for Cartesian Therapeutics we suggest using both methods to arrive at a better estimate.
Cartesian Therapeutics Cash |
|
Cartesian Therapeutics Total Value Analysis
Cartesian Therapeutics is at this time forecasted to have valuation of 45 M with market capitalization of 175.78 M, debt of 13.98 M, and cash on hands of 106.44 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cartesian Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
45 M | 175.78 M | 13.98 M | 106.44 M |
Cartesian Therapeutics Investor Information
About 60.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.33. Cartesian Therapeutics had not issued any dividends in recent years. The entity had 1:30 split on the 5th of April 2024. Based on the key indicators related to Cartesian Therapeutics' liquidity, profitability, solvency, and operating efficiency, Cartesian Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Cartesian Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cartesian Therapeutics has an asset utilization ratio of 8.95 percent. This indicates that the Company is making USD0.0895 for each dollar of assets. An increasing asset utilization means that Cartesian Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Cartesian Therapeutics Ownership Allocation
Cartesian Therapeutics holds a total of 26 Million outstanding shares. Cartesian Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cartesian Therapeutics Profitability Analysis
The company reported the previous year's revenue of 38.91 M. Net Loss for the year was (77.42 M) with loss before overhead, payroll, taxes, and interest of (51.76 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cartesian Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cartesian Therapeutics and how it compares across the competition.
About Cartesian Therapeutics Valuation
The stock valuation mechanism determines Cartesian Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Cartesian Therapeutics. We calculate exposure to Cartesian Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cartesian Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 38.9 M | 30 M | |
| Pretax Profit Margin | (1.98) | (2.08) | |
| Operating Profit Margin | (1.13) | (1.18) | |
| Net Loss | (1.99) | (2.09) | |
| Gross Profit Margin | 1.08 | 1.06 |
Cartesian Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 23.7 M | |
| Quarterly Earnings Growth Y O Y | -0.074 | |
| Forward Price Earnings | 25.4453 |
Cartesian Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Cartesian Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cartesian we look at many different elements of the entity such as Cartesian's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cartesian Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cartesian Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cartesian Therapeutics' worth.Complementary Tools for Cartesian Stock analysis
When running Cartesian Therapeutics' price analysis, check to measure Cartesian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cartesian Therapeutics is operating at the current time. Most of Cartesian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cartesian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cartesian Therapeutics' price. Additionally, you may evaluate how the addition of Cartesian Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |